Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry 610 other companies have achieved higher Quick Ratio than Rapid Therapeutic Science Laboratories Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 4650 to 5669.

Explain Quick Ratio?
How much Cash & cash equivalents PCHA�s has?
What are PCHA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PCHA Quick Ratio	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3	(Jun 30 2022) Q2
Y / Y Current Liabilities Change	-8.95 %	-12.91 %	232.91 %	139.8 %	941.93 %
Y / Y Cash & cash equivalent Change	-98.07 %	-46.73 %	-	-	134.07 %
Quick Ratio MRQ	0	0	-	-	0.02
PCHA's Total Ranking	# 5669	# 4650	# 0	# 0	# 5109
Seq. Current Liabilities Change	-0.83 %	-40.07 %	51.82 %	0.92 %	-5.15 %
Seq. Cash & cash equivalent Change	-87.71 %	-	-	-	240.05 %

Quick Ratio second quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 611
Healthcare Sector	# 1223
Overall Market	# 5669

Quick Ratio Statistics
High	Average	Low
1.44	0.18	0
(Mar 31 2021)		(Sep 30 2018)

Financial Statements
Rapid Therapeutic Science Laboratories Inc 's Current Liabilities	$ 4 Millions	Visit PCHA's Balance sheet
Rapid Therapeutic Science Laboratories Inc 's Cash & cash equivalent	$ 0 Millions	Visit PCHA's Balance sheet
Source of PCHA's Sales		Visit PCHA's Sales by Geography

Cumulative Rapid Therapeutic Science Laboratories Inc 's Quick Ratio

PCHA's Quick Ratio for the trailling 12 Months

PCHA Quick Ratio	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	48.88 %	119.54 %	357.99 %	377.95 %	466.39 %
Y / Y Cash & cash equivalent TTM Growth	-98.43 %	-89.13 %	-89.21 %	-79.56 %	25.98 %
Quick Ratio TTM	0	0.01	0.01	0.02	0.09
Total Ranking TTM	# 4664	# 3173	# 4288	# 3987	# 4590
Seq. Current Liabilities TTM Growth	-2.01 %	-2.96 %	30.42 %	20.04 %	44.51 %
Seq. Cash & cash equivalent TTM Growth	-84.79 %	-10.62 %	-57.01 %	-73.15 %	5.38 %

Quick ratio ranking by company, industry and sector >> Back to PCHA Financial Strength Comparisons >> Go to Compare PCHA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in PCHA's Current Liabilities to $4.43 millions, cumulative Quick Ratio to 0 below the PCHA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 581 other companies have achieved higher Quick Ratio than Rapid Therapeutic Science Laboratories Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3173 to 4664.

Explain Quick Ratio?
How much Cash & cash equivalents PCHA�s has?
What are PCHA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 582
Healthcare Sector	# 1169
Within the Market	# 4664

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.39	0.1	0
(Sep 30 2021)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2023 MRQ Cash & cash equivalent	Jun 30 2023 MRQ Current Liabilities
Skinvisible Inc	0.00	$ 0.004 Millions	$ 2.980 Millions
Aridis Pharmaceuticals Inc	0.00	$ 0.019 Millions	$ 20.394 Millions
Theralink Technologies Inc	0.00	$ 0.045 Millions	$ 48.081 Millions
Rebus Holdings Inc	0.00	$ 0.005 Millions	$ 5.619 Millions
60 Degrees Pharmaceuticals Inc	0.00	$ 0.019 Millions	$ 28.863 Millions
Respirerx Pharmaceuticals Inc	0.00	$ 0.007 Millions	$ 12.210 Millions
Rapid Therapeutic Science Laboratories Inc	0.00	$ 0.002 Millions	$ 4.426 Millions
IMPACT BIOMEDICAL INC.	0.00	$ 0.003 Millions	$ 12.055 Millions
Regen Biopharma Inc	0.00	$ 0.001 Millions	$ 5.314 Millions

Date modified: 2026-09-08T15:11:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.